Roslin Cell Therapies Ltd. (RoslinCT). (5/23/22). "Press Release: RoslinCT Announces the Appointment of Peter Coleman as CEO". Edinburgh.

	Organisation	Roslin Cell Therapies Ltd. (RoslinCT)
	Group	RoslinCT (Group)
	Organisation 2	Cobra Biologics Ltd.
	Group	Charles River (Group)
	Product	CDMO (CAGT)
	Product 2	cell and gene therapy manufacturing (CGT manufacturing)
	Index term 2	RoslinCT–GHO Capital: investment, 202201 (majority?) investment by GHO Capital Partners LLP
	Person	Coleman, Peter (RoslinCT 202208– CEO joined 3/22 before Cobra Biologics 201106 CEO– before RecipharmCobra Biologics)
	Person 2	Downie, Janet (Roslin Cell Therapies 202006 CEO)

RoslinCT - a cell and gene therapy/ATMP CDMO, developing life-changing cell and gene therapies in Edinburgh’s BioQuarter – announces today the appointment of Peter Coleman as CEO.

The company is also pleased that Janet Downie will remain as a director of the business and has been promoted to a more strategic board position to help steer the future direction, whilst allowing her to spend more time with her family.

Peter joined RoslinCT in March 2022 to support the business with its Global Expansion Plans. Prior to that, he was the CEO of Cobra Biologics a position he held from 2011 to Mar 2021 when the business was sold. Peter is a qualified accountant with an MBA and has over 20 years of Advanced Therapy CDMO experience as both CFO and CEO. During his time as CEO of Cobra he oversaw multiple corporate transactions, alongside a rapid growth in order book as the business focussed on Advanced Therapies.

He is an active member of the UK life science infrastructure as an MMIP representative. He is also a multiple award winner, with the Queen’s Award for Enterprise, International Trade in 2017 and joint winner of the BIA Richard Wilson Impact Award in 2020 for his involvement in the BIA’s UK COVID Vaccine Taskforce.

RoslinCT has now entered a new and exciting phase of growth alongside investors, GHO Capital Partners to become a global leader in the cell & gene therapy space building on the great science, capabilities and hard work so far. Since the investment from GHO, we have already seen tremendous growth in the company and further building of the senior team. This puts RoslinCT in an even stronger position to continue to partner with existing and new customers and provide life-changing and life-saving cell therapies for our patients.

Peter Coleman said: “It is a real honour to be the new CEO of RoslinCT, the business has a tremendous track record and history, founded on innovation and excellent customer service. Janet and the RoslinCT team have done a fantastic job growing the business thus far. With the recent investment and ongoing support of GHO our aim is to take the business to a global CDMO leadership with the ultimate aim of saving patient lives”

Janet Downie said: “I am delighted to welcome Peter to the business and I am excited to be able to continue to contribute to RoslinCT development, whilst benefiting from greater flexibility to spend more time with my family. I look forward to participating in the next phase of growth for RoslinCT and maximise the potential of the business and seeing it truly recognised as a world leader in the field and the CDMO partner of choice”.

Ian McCubbin said: “This is a great day for RoslinCT not only do we gain a motivated, outstanding and experienced new CEO in Peter but we also retain the capability, knowledge and passion that Janet has built up as she has grown the business. These are exciting times for RoslinCT as we continue on our growth trajectory in the amazing sector of advanced therapies, based here in the UK. The treatments we make can bring transformational patient benefit and positive economic contribution.”

ENDS

About RoslinCT

RoslinCT is a leading UK Cell Therapy Contract Development and Manufacturing Organisation (CDMO) focused on providing services for companies developing cell-based therapeutic products. Originally founded in 2006 as a spin-out from the Roslin Institute, we built on the broad range of scientific expertise available in the field of cell biology. Based at the Edinburgh BioQuarter, we operate fully licensed GMP manufacturing facilities and have a proven track record in the delivery of cell-based products. www.roslinct.com.

About GHO Capital

Global Healthcare Opportunities, or GHO Capital Partners LLP, is a leading specialist healthcare investment advisor based in London. We apply global capabilities and perspectives to unlock high growth healthcare opportunities, targeting Pan-European and transatlantic internationalisation to build market leading businesses of strategic global value. Our proven investment track record reflects the unrivalled depth of our industry expertise and network. We partner with strong management teams to generate long-term sustainable value, improving the efficiency of healthcare delivery to enable better, faster, more accessible healthcare. For further information, please visit www.ghocapital.com.

Record changed: 2024-01-06